All In Biotech

Drug Trial Radar · NCT01478178

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma

Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

Oct 2011

Primary completion

Dec 2015

Study completion Oct 2016

Sponsor

Lead sponsor
Kintara Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma. Pharmacokinetic (PK) properties will be explored and tumor responses to treatment will be evaluated.

Conditions

  • Glioma
  • Glioblastoma
  • Glioblastoma Multiforme
  • GBM
  • Brain Cancer

Interventions

  • VAL-083 (Dianhydrogalactitol)Drug

    VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of maximum tolerated dose (MTD)Time frame: Study Day 35

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco, Division of Neuro-Oncology

    San Francisco, California

  • Sarah Cannon Research Institute

    Denver, Colorado

  • Florida Cancer Specialists

    Sarasota, Florida

  • Mayo Clinic

    Rochester, Minnesota

  • Sarah Cannon Research Institute

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.